Axa’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Axa’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-55,656	Closed	-$6.6M	–	1260
2022 Q1	$6.6M	Sell	55,656 -5,391	-9%	-$672K	0.02%	573
2021 Q4	$8.41M	Buy	61,047 +8,656	+17%	+$1.1M	0.02%	540
2021 Q3	$7.28M	Buy	52,391 +10,460	+25%	+$1.31M	0.02%	582
2021 Q2	$4.07M	Sell	41,931 -3,185	-7%	-$258K	0.01%	755
2021 Q1	$3.08M	Buy	45,116 +821	+2%	+$66.4K	0.01%	780
2020 Q4	$3.8M	Sell	44,295 -23,809	-35%	-$2.02M	0.01%	747
2020 Q3	$4.43M	Sell	68,104 -657	-1%	-$43.1K	0.02%	660
2020 Q2	$5.03M	Buy	68,761 +4,148	+6%	+$221K	0.02%	610
2020 Q1	$2.2M	Buy	+64,613	New	+$2.95M	0.01%	713
2018 Q1	–	Sell	-130,484	Closed	-$3.52M	–	1468
2017 Q4	$3.52M	Buy	+130,484	New	+$3.59M	0.01%	739

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa's BHVN Position: Q2 2022 in Review

Axa sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 55,656 shares — an estimated $6.6M sold.

Axa first reported a position in BHVN in Q4 2017 and held it in 10 quarters. The position peaked at $8.41M in Q4 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Axa reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Axa sold 55,656 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $6.6M.
Axa first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 10 quarters.
Axa's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $8.41M in Q4 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Axa's 13F filing for Q2 2022, filed 15 Aug 2022.